Akero Therapeutics (NASDAQ: AKRO)
Akero Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Akero Therapeutics Company Info
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
News & Analysis
This Stock Just Doubled in 1 Day -- Is It Still a Buy?
Why Akero Therapeutics Shares Are Slumping This Week
Akero's lead therapy fell short of its goals in a phase 2b trial to treat NASH.
Why Akero Therapeutics Stock Is Crashing Today
Investors are bailing on the biotech stock after disappointing clinical results for experimental NASH drug efruxifermin (EFX).
Why Akero Therapeutics Stock Is on Fire Today
The biotech's experimental NASH drug hit the mark in a key phase 2b trial.
Could This Obscure Biotech Stock Make Early Investors a Fortune?
If you haven't heard of Akero Therapeutics before, take note. Its NASH drug candidate could be a game changer.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.